- Home
- ENTX vs SFWL Comparison
ENTX vs SFWL Comparison
Compare ENTX & SFWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- SFWL
- Stock Information
- Founded
- ENTX 2010
- SFWL 2001
- Country
- ENTX Israel
- SFWL China
- Employees
- ENTX N/A
- SFWL N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- SFWL Trucking Freight/Courier Services
- Sector
- ENTX Health Care
- SFWL Industrials
- Exchange
- ENTX Nasdaq
- SFWL Nasdaq
- Market Cap
- ENTX 104.0M
- SFWL 81.0M
- IPO Year
- ENTX 2018
- SFWL 2023
- Fundamental
- Price
- ENTX $1.99
- SFWL $1.02
- Analyst Decision
- ENTX Strong Buy
- SFWL
- Analyst Count
- ENTX 1
- SFWL 0
- Target Price
- ENTX $10.00
- SFWL N/A
- AVG Volume (30 Days)
- ENTX 37.1K
- SFWL 9.4K
- Earning Date
- ENTX 08-08-2025
- SFWL 07-07-2025
- Dividend Yield
- ENTX N/A
- SFWL N/A
- EPS Growth
- ENTX N/A
- SFWL 4.79
- EPS
- ENTX N/A
- SFWL 0.13
- Revenue
- ENTX $223,000.00
- SFWL $504,158,000.00
- Revenue This Year
- ENTX N/A
- SFWL N/A
- Revenue Next Year
- ENTX N/A
- SFWL N/A
- P/E Ratio
- ENTX N/A
- SFWL $7.35
- Revenue Growth
- ENTX N/A
- SFWL 24.75
- 52 Week Low
- ENTX $1.41
- SFWL $0.86
- 52 Week High
- ENTX $2.79
- SFWL $1.60
- Technical
- Relative Strength Index (RSI)
- ENTX 49.71
- SFWL 46.91
- Support Level
- ENTX $1.91
- SFWL $0.91
- Resistance Level
- ENTX $2.06
- SFWL $1.02
- Average True Range (ATR)
- ENTX 0.17
- SFWL 0.04
- MACD
- ENTX -0.00
- SFWL -0.00
- Stochastic Oscillator
- ENTX 36.36
- SFWL 54.27
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.